Background: To correctly estimate the cost-effectiveness of treatments that reduce COPD exacerbations, the utility gains from preventing exacerbations need to be measured. This requires utility measurement during exacerbations.

Aim: To assess the ability of the EQ-5D to detect the recovery from moderate COPD exacerbations.

Methods: In the US, 65 COPD and/or chronic bronchitis patients (≥40 years old smokers or ex-smokers with a history of 10 pack-years) were enrolled within 48 h of symptom onset of the exacerbation. Patients completed the EQ-5D at enrollment and after 7, 14 and 42 days. Symptoms and medication use were recorded in diaries. Change over time and loss of quality-adjusted life years (QALYs) due to the exacerbation was estimated. Using standardized response mean (SRM) as the metric of responsiveness, we compared the responsiveness of the EQ-5D to the responsiveness of morning peak expiratory flow rate, rescue medication use and symptom scores. SRMs were also used to assess whether patients with greater improvements in peak expiratory flow rate, rescue medication use, symptom scores, clinician global impression of change, and patient global impression of change had a greater improvement in EQ-5D than patients with smaller improvement.

Results: Mean utility index scores (standard deviation) using the US value set were 0.683 (0.209), 0.726 (0.216), 0.768 (0.169) and 0.760 (0.181) at days 1, 7, 14 and 42, respectively. The mean of each patient's lowest index score, either at visit 1 or visit 2, was 0.651 (0.213). Over the course of 6 weeks there was a highly significant improvement in mean utility. The greatest improvement was seen between day 7 and day 14. Patients lost on average 0.00896 QALY (0.0086) or 3.27 (3.13) quality-adjusted life days during the exacerbation. The EQ-5D (SRM: 0.653) was more responsive to change than peak expiratory flow (0.269), rescue medication use (0.343) and sputum symptom scores (0.322) and equally responsive as cough (0.587) and dyspnea (0.638) symptom scores.

Conclusion: The EQ-5D is responsive to the recovery from a moderate COPD exacerbation.

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.rmed.2011.02.018DOI Listing

Publication Analysis

Top Keywords

recovery moderate
12
moderate copd
12
peak expiratory
12
expiratory flow
12
rescue medication
12
symptom scores
12
eq-5d responsive
8
responsive recovery
8
quality-adjusted life
8
flow rate
8

Similar Publications

While the coronavirus disease 2019 (COVID-19) pandemic has declined, many survivors continue to suffer debilitating symptoms, such as fatigue, pain, and foggy thoughts. Sustained COVID-19 symptoms, or Long COVID, challenge health care resources and economic recovery. This article describes the methodology, implementation, and results of an observational study investigating how time since diagnosis may affect lingering symptoms among the adult COVID-19 population.

View Article and Find Full Text PDF

Background: Therapeutic advancements for the polyglutamine diseases, particularly spinocerebellar degeneration, are eagerly awaited. We evaluated the safety, tolerability, and therapeutic effects of L-arginine, which inhibits the conformational change and aggregation of polyglutamine proteins, in patients with spinocerebellar ataxia type 6 (SCA6).

Methods: A multicenter, randomized, double-blind, placebo-controlled phase 2 trial (clinical trial ID: AJA030-002, registration number: jRCT2031200135) was performed on 40 genetically confirmed SCA6 patients enrolled between September 1, 2020, and September 30, 2021.

View Article and Find Full Text PDF

Miller Fisher syndrome (MFS) is a rare Guillain-Barré syndrome (GBS) variant. The global incidence of GBS is approximately one to two in 100,000 children (aged 0 to 15 years) per year. Miller Fisher syndrome represents a further small subset, with the incidence being one to two in 1,000,000 children.

View Article and Find Full Text PDF

: Recovery management checkups done in primary care settings (RMC-PCs) can be an effective intervention to link individuals with substance use disorders (SUD) to treatment and help them stay engaged with treatment. There is reason to question, however, whether RMC-PCs are as effective for those who have been recently incarcerated or for those holding a minoritized, racial identity. : We examined data from a randomized controlled trial of RMC-PCs compared to a control condition ( = 266).

View Article and Find Full Text PDF

Solvometallurgical recovery of antimony from waste polyvinyl chloride plastic and co-extraction of organic additives.

RSC Adv

January 2025

Waste Recycling Technologies, Materials & Chemistry Unit, Flemish Institute for Technological Research, VITO N.V. Boeretang 200 B-2400 Mol Belgium

Antimony is a critical raw material in Europe wherein for 43% of its market share it is applied in the form of antimony trioxide as a fire retardant in plastics. Currently, antimony recycling from waste plastics does not take place and has been scarcely studied. In this work, a process was developed to extract antimony from a soft PVC material and recover it as SbClO.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!